- Home
- MRK vs AZN Comparison
MRK vs AZN Comparison
Compare MRK & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRK
- AZN
- Stock Information
- Founded
- MRK 2000
- AZN 1992
- Country
- MRK United States
- AZN United Kingdom
- Employees
- MRK N/A
- AZN N/A
- Industry
- MRK Biotechnology: Pharmaceutical Preparations
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- MRK Health Care
- AZN Health Care
- Exchange
- MRK Nasdaq
- AZN Nasdaq
- Market Cap
- MRK 218.2B
- AZN 205.5B
- IPO Year
- MRK N/A
- AZN 1993
- Fundamental
- Price
- MRK $76.82
- AZN $72.83
- Analyst Decision
- MRK Buy
- AZN Strong Buy
- Analyst Count
- MRK 15
- AZN 5
- Target Price
- MRK $113.71
- AZN $92.33
- AVG Volume (30 Days)
- MRK 14.7M
- AZN 5.0M
- Earning Date
- MRK 04-24-2025
- AZN 07-24-2025
- Dividend Yield
- MRK 4.22%
- AZN 2.12%
- EPS Growth
- MRK 667.14
- AZN 22.71
- EPS
- MRK 6.88
- AZN 4.97
- Revenue
- MRK $63,922,000,000.00
- AZN $54,982,000,000.00
- Revenue This Year
- MRK $2.42
- AZN $9.56
- Revenue Next Year
- MRK $5.64
- AZN $6.09
- P/E Ratio
- MRK $11.17
- AZN $28.82
- Revenue Growth
- MRK 4.10
- AZN 15.48
- 52 Week Low
- MRK $73.31
- AZN $61.24
- 52 Week High
- MRK $134.63
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- MRK 44.17
- AZN 61.90
- Support Level
- MRK $75.59
- AZN $69.97
- Resistance Level
- MRK $78.20
- AZN $71.41
- Average True Range (ATR)
- MRK 2.03
- AZN 1.22
- MACD
- MRK 0.21
- AZN 0.42
- Stochastic Oscillator
- MRK 44.10
- AZN 94.74
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.